Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug afimkibart tested for Long-Term safety in new study

NCT ID NCT07223697

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effects may occur. The goal is to understand if afimkibart remains safe and helpful for ongoing management of the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study Parent Clinical Trial-Specific Criteria: * Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved =\> EASI50 response from study baseline Exclusion Criteria: * Evidence of other skin conditions that would interfere with the assessment of AD * Withdrawal of consent and/or premature discontinuation from parent study * Any permanent discontinuation of study drug in parent study * History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria delle Marche

    RECRUITING

    Ancona, The Marches, 60126, Italy

  • Best Skin Research LLC

    RECRUITING

    Camp Hill, Pennsylvania, 17011, United States

  • Centro de Estudos em Terapias Inovadoras ? CETI

    RECRUITING

    Curitiba, Paraná, 80030-110, Brazil

  • Centro de Pesquisa São Lucas

    RECRUITING

    Campinas, São Paulo, 13060-803, Brazil

  • Centrum Medyczne Pratia Gdynia

    RECRUITING

    Gdynia, 81-338, Poland

  • Centrum Medyczne Pratia Katowice I

    RECRUITING

    Katowice, Silesian Voivodeship, 40-081, Poland

  • Centrum Nowoczesnych Terapii "Dobry Lekarz"

    RECRUITING

    Krakow, 31-011, Poland

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • DermEdge

    RECRUITING

    Mississauga, Ontario, L4Y4C5, Canada

  • DermEffects

    RECRUITING

    London, Ontario, N6H 5L5, Canada

  • Dermatologikum Hamburg Gemeinschaftspraxis GbR

    RECRUITING

    Hamburg, 20354, Germany

  • Dermatology Research Associate

    RECRUITING

    Los Angeles, California, 90045, United States

  • Fachklinik Bad Bentheim

    RECRUITING

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    RECRUITING

    Sao Jose Rio Preto, São Paulo, 15090-000, Brazil

  • HMCG - Hospital e Maternidade Dr. Christovo da Gama

    RECRUITING

    Santo Andr, São Paulo, 09030-010, Brazil

  • Hamilton Research, LLC

    RECRUITING

    Alpharetta, Georgia, 30022, United States

  • Hospital Universitario Reina Sofia

    RECRUITING

    Córdoba, 14004, Spain

  • Hospital de Clnicas de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A

    RECRUITING

    Rio de Janeiro, 20241-180, Brazil

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90020-090, Brazil

  • Klinika Ambroziak Dermatologia

    RECRUITING

    Warsaw, 02-953, Poland

  • Lynderm Research Inc

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Olympian Clinical Research

    RECRUITING

    Tampa, Florida, 33615, United States

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

  • Ryan Clinical Research Inc

    RECRUITING

    Newmarket, Ontario, L3Y 5G8, Canada

  • Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski

    RECRUITING

    Krakow, 30-002, Poland

  • UCLA Division of Dermatology

    RECRUITING

    Los Angeles, California, 90024, United States

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    RECRUITING

    Botucatu, São Paulo, 18618-686, Brazil

  • Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie

    RECRUITING

    Rzeszów, 35-055, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.